MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Adaptimmune Therapeutics plc (NASDAQ: ADAP)*
Organization & Developments: Adaptimmune Therapeutics
• Prelude Therapeutics
Parents
Adaptimmune Therapeutics plc (NASDAQ: ADAP)*
Children
2018: Adaptimmune shares boosted by new signs of success with TCR cell therapy – Endpoints News
2018: Adaptimmune Therapeutics (ADAP) seekingalpha.com
2020: Adaptimmune Therapeutics: Mega Profitability
2020: Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors, Speculative Investment
2020: Biotech Analysis Central Preview Series: Adaptimmune-seekingalpha.com
2021: Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs
2021: Our Take On Adaptimmune Therapeutics
2022: Adaptimmune Therapeutics: A Little More Patience May Be Profitable_seekingalpha.com
2022: Adaptimmune Therapeutics: Depressed Despite Upcoming BLA_seekingalpha.com
2022: Adaptimmune to lay off up to 30% of staff as allogeneic ambitions stunted by cell line change
2022: Adaptimmune: The Afamicel Rolling BLA Is Its Lifeline_ seekingalpha.com
2024: Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study
2024: Adaptimmune Reports $41M Q3 Revenue, Plans 33% Staff Cut to Save $300M
2024: Adaptimmune: Drug Approval Now Imminent?
2024: Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
2024: Adaptimmune’s Strategic Shift and Financial Update_www.tipranks.com
2025: Adaptimmune, seeking to stay afloat, sells off cell therapies
2025: Adaptimmune's Groundbreaking Cell Therapy Assets Acquired by US WorldMeds in $85M Strategic Deal
Jumps
*Key People: Adaptimmune Therapeutics
Finance & Acquisitions: Adaptimmune Therapeutics